Alamar Biosciences stock overview

Alamar Biosciences (ALMR) stock recently traded at US$23.66, with the past week showing a decline of 5.5% and a small 0.8% pullback over the latest trading day.

For investors tracking this newly listed proteomics company, the stock’s moves sit against a backdrop of US$74.21 million in revenue and a reported net loss of US$29.82 million, reflecting an early stage commercial profile.

Recent trading has been a bit choppy, with the share price return down 0.8% over the last day and 5.5% over the week. The year to date share price return of 7.6% suggests early momentum that has cooled in the very short term as investors reassess growth prospects against ongoing losses.

If you are looking at Alamar and wondering what else is moving in high growth health technology, this is a good moment to scan 35 healthcare AI stocks.

So, with Alamar Biosciences generating US$74.21 million in revenue but still reporting a US$29.82 million net loss, is the current share price overlooking future growth potential, or is the market already pricing it in?

Preferred Price-to-Sales of 21.7x: Is it justified?

On a P/S basis, Alamar Biosciences trades at 21.7x, which is high relative to its latest close at $23.66 and points to a rich valuation compared with peers.

The P/S ratio compares the company’s market value to its revenue and is often used for younger or unprofitable businesses where earnings are still negative. For a proteomics platform selling instruments, consumables and services across research and diagnostics, investors often lean on revenue-based metrics while the business is still loss making.

Here, Alamar is unprofitable, carries a reported net loss of $29.82 million and has less than one year of cash runway. Yet the stock trades on a P/S of 21.7x. That suggests investors are willing to pay a substantial premium for its $74.21 million of revenue, despite the lack of visibility on future earnings or analyst forecasts.

The comparison with peers is stark. Alamar’s 21.7x P/S is roughly three times the peer average of 7.3x and more than six times the US Life Sciences industry average of 3.4x, implying the market is assigning a much higher revenue multiple than the sector norm.

Result: Price-to-Sales of 21.7x (OVERVALUED)

However, the story could change quickly if the company’s net loss of US$29.82 million widens or cash needs rise before earnings visibility improves.

Next Steps

If this combination of premium pricing, early-stage losses and limited earnings visibility leaves you unsure, act while the data is fresh and shape your own view with 1 key reward and 3 important warning signs

Looking for more investment ideas?

Do not stop with a single stock when there are many other opportunities that could fit your goals just as well or even better.

• Target stability and growth potential by checking companies in the solid balance sheet and fundamentals stocks screener (46 results) that combine financial strength with room to grow.
• Hunt for potential bargains by scanning 50 high quality undervalued stocks that may offer quality at prices the broader market is overlooking.
• Spot early-stage opportunities with lower share prices through the 25 elite penny stocks with strong financials that still meet strict financial standards.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.